Biogen Inc. (NASDAQ:BIIB) Shares Sold by B&D White Capital Company LLC

B&D White Capital Company LLC reduced its holdings in Biogen Inc. (NASDAQ:BIIB) by 16.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,500 shares of the biotechnology company’s stock after selling 300 shares during the quarter. B&D White Capital Company LLC’s holdings in Biogen were worth $229,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Pacer Advisors Inc. boosted its stake in Biogen by 13,574.7% in the fourth quarter. Pacer Advisors Inc. now owns 2,667,531 shares of the biotechnology company’s stock valued at $407,919,000 after acquiring an additional 2,648,024 shares during the period. Van ECK Associates Corp lifted its holdings in shares of Biogen by 977.9% in the 4th quarter. Van ECK Associates Corp now owns 1,066,460 shares of the biotechnology company’s stock worth $163,083,000 after purchasing an additional 967,523 shares during the last quarter. Mizuho Securities USA LLC boosted its position in Biogen by 2,715.9% during the 3rd quarter. Mizuho Securities USA LLC now owns 316,000 shares of the biotechnology company’s stock valued at $61,253,000 after purchasing an additional 304,778 shares during the period. Erste Asset Management GmbH bought a new position in Biogen during the 3rd quarter worth $55,826,000. Finally, State Street Corp increased its position in Biogen by 3.5% in the third quarter. State Street Corp now owns 7,344,960 shares of the biotechnology company’s stock worth $1,423,747,000 after buying an additional 248,942 shares during the period. 87.93% of the stock is currently owned by institutional investors.

Biogen Stock Up 2.6 %

Shares of Biogen stock opened at $140.64 on Monday. Biogen Inc. has a 12-month low of $128.51 and a 12-month high of $238.00. The firm has a market capitalization of $20.59 billion, a PE ratio of 12.57, a price-to-earnings-growth ratio of 1.47 and a beta of -0.08. The company has a quick ratio of 0.90, a current ratio of 1.35 and a debt-to-equity ratio of 0.27. The stock’s fifty day moving average is $145.16 and its 200-day moving average is $170.41.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 EPS for the quarter, beating analysts’ consensus estimates of $3.43 by $0.01. Biogen had a net margin of 16.87% and a return on equity of 14.98%. Equities analysts anticipate that Biogen Inc. will post 15.83 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on BIIB. William Blair reiterated an “outperform” rating on shares of Biogen in a research note on Monday, January 13th. Mizuho reduced their target price on shares of Biogen from $251.00 to $207.00 and set an “outperform” rating for the company in a research note on Thursday, November 21st. Citigroup dropped their price target on shares of Biogen from $160.00 to $145.00 and set a “neutral” rating on the stock in a research note on Thursday, February 13th. Scotiabank reduced their price objective on Biogen from $244.00 to $224.00 and set a “sector outperform” rating for the company in a research report on Thursday, February 13th. Finally, Barclays decreased their price objective on Biogen from $190.00 to $180.00 and set an “equal weight” rating for the company in a report on Thursday, October 31st. Seventeen investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat.com, Biogen has an average rating of “Hold” and a consensus target price of $213.33.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.